Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Wallace

Executive Editor

Generics Bulletin Executive Editor Dave Wallace has more than 10 years' experience of reporting on the global generics, biosimilars and value-added medicines industries. Having begun his career in the European chemicals industry, Dave has now spent over a decade with Generics Bulletin, becoming editor from 2018. Bringing his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and acts as a judge for the annual Global Generics & Biosimilars Award.

Latest From David Wallace

UK Pioneers Tailored Biosimilars Pathway With Fresh Guidance

Updated guidance on the UK’s new licensing pathway for biosimilars – which will typically not require comparative efficacy data – has been published by the MHRA after a stakeholder consultation. It has been warmly welcomed by the off-patent industry both locally and internationally.

Biosimilars Review Pathway

Perrigo Rx Divestment Remains ‘On Track’

Perrigo says its deal to divest its Rx business remains “on track,” with the company shunting the prescription unit into “discontinued operations” in the first quarter as it trains its focus on the firm’s future growth engine of consumer self-care.

Deals Strategy

Medicines Patent Pool Prepared To Step In On Vaccines

The Medicines Patent Pool says it is ready to step in to assist with voluntary licensing and technology transfer around COVID-19 vaccines, following US support for an IP waiver.

Intellectual Property Coronavirus COVID-19

Etoricoxib Leads Biggest UK Price Rises In April

Etoricoxib led the steepest price rises for UK generics in April, with the non-steroidal anti-inflammatory drug seeing average prices almost double.

Market Intelligence Pricing Strategies

UK Pioneers Tailored Biosimilars Pathway With Fresh Guidance

Updated guidance on the UK’s new licensing pathway for biosimilars – which will typically not require comparative efficacy data – has been published by the MHRA after a stakeholder consultation, receiving a warm welcome from the off-patent industry both locally and internationally.

Biosimilars Review Pathway

Alvotech Attacks AbbVie Over Adalimumab

Alvotech has launched a US legal challenge over intellectual property around AbbVie’s Humira, claiming that the company enjoys a “wrongful monopoly” on the top-selling arthritis treatment for which the biosimilars company is developing a high-concentration adalimumab rival.

Biosimilars Intellectual Property
See All
UsernamePublicRestriction

Register